Literature DB >> 22684912

Metabolism of anandamide into eoxamides by 15-lipoxygenase-1 and glutathione transferases.

Pontus K A Forsell1, Asa Brunnström, Malin Johannesson, Hans-Erik Claesson.   

Abstract

Human 15-lipoxygenase-1 (15-LO-1) can metabolize arachidonic acid (ARA) into pro-inflammatory mediators such as the eoxins, 15-hydroperoxyeicosatetraenoic acid (HPETE), and 15-hydroxyeicosatetraenoyl-phosphatidylethanolamine. We have in this study investigated the formation of various lipid hydroperoxide by either purified 15-LO-1 or in the Hodgkin lymphoma cell line L1236, which contain abundant amount of 15-LO-1. Both purified 15-LO-1 and L1236 cells produced lipid hydroperoxides more efficiently when anandamide (AEA) or 2-arachidonoyl-glycerol ester was used as substrate than with ARA. Furthermore, L1236 cells converted AEA to a novel class of cysteinyl-containing metabolites. Based on RP-HPLC, mass spectrometry and comparison to synthetic products, these metabolites were identified as the ethanolamide of the eoxin (EX) C(4) and EXD(4). By using the epoxide EXA(4)-ethanol amide, it was also found that platelets have the capacity to produce the ethanolamide of EXC(4) and EXD(4). We suggest that the ethanolamides of the eoxins should be referred to as eoxamides, in analogy to the ethanolamides of prostaglandins which are named prostamides. The metabolism of AEA into eoxamides might engender molecules with novel biological effects. Alternatively, it might represent a new mechanism for the termination of AEA signalling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684912     DOI: 10.1007/s11745-012-3684-z

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  62 in total

1.  Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.

Authors:  Pattipati S Naidu; Steven G Kinsey; Tai L Guo; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2010-04-07       Impact factor: 4.030

2.  Human umbilical vein endothelial cells generate leukotriene C4 via microsomal glutathione S-transferase type 2 and express the CysLT(1) receptor.

Authors:  M Sjöström; P J Jakobsson; M Heimburger; J Palmblad; J Z Haeggström
Journal:  Eur J Biochem       Date:  2001-05

3.  12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway.

Authors:  Lei Zhao; Domenico Praticò; Daniel J Rader; Colin D Funk
Journal:  Prostaglandins Other Lipid Mediat       Date:  2005-09-12       Impact factor: 3.072

4.  Polychlorinated biphenyls induce arachidonic acid release in human platelets in a tamoxifen sensitive manner via activation of group IVA cytosolic phospholipase A2-alpha.

Authors:  Pontus K A Forsell; Anders O Olsson; Erik Andersson; Laxman Nallan; Michael H Gelb
Journal:  Biochem Pharmacol       Date:  2005-11-14       Impact factor: 5.858

Review 5.  Inflammation and immune regulation by 12/15-lipoxygenases.

Authors:  Hartmut Kühn; Valerie B O'Donnell
Journal:  Prog Lipid Res       Date:  2006-03-31       Impact factor: 16.195

Review 6.  Leukotriene C(4) synthase.

Authors:  Bing K Lam
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003 Aug-Sep       Impact factor: 4.006

7.  Expression of 15-lipoxygenase type-1 in human mast cells.

Authors:  Magdalena Gulliksson; Asa Brunnström; Malin Johannesson; Linda Backman; Gunnar Nilsson; Ilkka Harvima; Barbro Dahlén; Maria Kumlin; Hans-Erik Claesson
Journal:  Biochim Biophys Acta       Date:  2007-06-23

8.  15-lipoxygenase inhibitors as anti-atherosclerosis agents.

Authors:  J A Cornicelli
Journal:  IDrugs       Date:  1998-06

9.  Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor.

Authors:  A J Hampson; W A Hill; M Zan-Phillips; A Makriyannis; E Leung; R M Eglen; L M Bornheim
Journal:  Biochim Biophys Acta       Date:  1995-11-16

10.  Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure.

Authors:  Yosuke Kayama; Tohru Minamino; Haruhiro Toko; Masaya Sakamoto; Ippei Shimizu; Hidehisa Takahashi; Sho Okada; Kaoru Tateno; Junji Moriya; Masataka Yokoyama; Aika Nojima; Michihiro Yoshimura; Kensuke Egashira; Hiroyuki Aburatani; Issei Komuro
Journal:  J Exp Med       Date:  2009-06-22       Impact factor: 14.307

View more
  5 in total

Review 1.  The rise and fall of anandamide: processes that control synthesis, degradation, and storage.

Authors:  Roger Gregory Biringer
Journal:  Mol Cell Biochem       Date:  2021-03-13       Impact factor: 3.396

Review 2.  The Biosynthesis of Enzymatically Oxidized Lipids.

Authors:  Ali A Hajeyah; William J Griffiths; Yuqin Wang; Andrew J Finch; Valerie B O'Donnell
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-19       Impact factor: 5.555

3.  Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.

Authors:  Katarzyna Starowicz; Wioletta Makuch; Michal Korostynski; Natalia Malek; Michal Slezak; Magdalena Zychowska; Stefania Petrosino; Luciano De Petrocellis; Luigia Cristino; Barbara Przewlocka; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

4.  Expression of matrix metalloproteinases and components of the endocannabinoid system in the knee joint are associated with biphasic pain progression in a rat model of osteoarthritis.

Authors:  Agnieszka Pajak; Magdalena Kostrzewa; Natalia Malek; Michal Korostynski; Katarzyna Starowicz
Journal:  J Pain Res       Date:  2017-08-21       Impact factor: 3.133

Review 5.  Endocannabinoid System and Its Regulation by Polyunsaturated Fatty Acids and Full Spectrum Hemp Oils.

Authors:  Slavko Komarnytsky; Thirumurugan Rathinasabapathy; Charles Wagner; Brandon Metzger; Carolina Carlisle; Chinmayee Panda; Sara Le Brun-Blashka; John P Troup; Saradhadevi Varadharaj
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.